Myelofibrosis

FOI REFERENCE: 24207    FOI DATE: 4^th July 2024    

Are researching the treatment of myeloproliferative neoplasms. We would greatly appreciate if you could answer the following questions:

Q1. Please provide the total number of patients treated in the last 6 months for:  

• Polycythaemia Vera (ICD10 code D45) 80
• Myelofibrosis (ICD10 code D47.4) 12
• Myelofibrosis (ICD10 code D47.4) patients aged 65 and older 9

Q2. How many patients were treated in the past 6 months (for any disease) with:  

• Ruxolitinib                   20 Patients
• Fedratinib                    * Patients      
• Momelotinib                 0 Patients

Q3. How many patients were treated in the past 6 months for Myelofibrosis (ICD10 code D47.4) with:

• Ruxolitinib                   17 Patients
• Fedratinib                    * Patients
• Momelotinib                 0 Patients

Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?  

• Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?  0 Patients
• Of these patients, how many were treated in the past 6 months with Interferon therapy?  0 Patients
• Of these patients, how many have received no active treatment in the past 6 months? Data not available

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.  Worcestershire Acute Hospitals NHS Trust don’t have any trials in Myelofibrosis at present. 

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018